A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in
combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK),
immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult
subjects with advanced NSCLC.

Inclusion Criteria:

1. Age ≥ 18 years

2. Advanced non-small cell lung cancer

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

4. Adequate organ and marrow function

Exclusion Criteria:

1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
treatment

2. Current or prior use of immunosuppressive medication within 14 days before the first
dose of study drugs

3. Active or prior documented autoimmune disease within the last 2 years.